Unlocking Value: 10 Must-Research Stocks!
Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on Dow Inc. (DOW)
Date: January 29, 2026 (United States)
Market anchor: 10‑year U.S. Treasury ≈ 4.24–4.26% this week; we use 4.25% as the risk‑free rate. Federal Reserve H.15, daily update January 28, 2026. (federalreserve.gov)
1) Ten value‑based candidates to research now
Screen: resilient or improving free cash flow, visible self‑help/cost programs, balance‑sheet discipline, and a discount to conservative intrinsic value.
- PPG Industries (PPG) — steady execution with 2025 EPS up and 2026 guide for mid‑single‑digit EPS growth; portfolio simplification and cost saves continue. (news.ppg.com)
- Eastman Chemical (EMN) — cyclically depressed but improving mix (advanced materials, circular plastics); 2025 EBIT margins improved; shares sold off on mid‑2025 miss. (eastman.com)
- LyondellBasell (LYB) — heavy cycle pressure but strong cash actions and portfolio pruning; 2026 capex cut and cost plan to $1.1B by end‑2026. (investors.lyondellbasell.com)
- Westlake (WLK) — disciplined capital returns and long dividend history; trades around 8–10x EV/EBITDA through the trough. (westlake.com)
- Olin (OLN) — chlor‑alkali at a low point; updated Q4‑25 EBITDA warning creates entry point; watch Freeport uptime and chlorine demand. (prnewswire.com)
- Huntsman (HUN) — restructuring, dividend reset, and >$100M cost program; levered to construction recovery. (huntsman.com)
- RPM International (RPM) — specialty coatings compounder with record FY25 results and FY26 growth outlook. (businesswire.com)
- Air Products (APD) — de‑risking megaproject exposure; volatility around asset sales/partnerships could create mispricing. (wsj.com)
- Celanese (CE) — sharp reset on weak outlook in 2024; watch acetic chain recovery and deleveraging cadence. (investopedia.com)
- Dow Inc. (DOW) — deep cyclical trough, dividend reset, large self‑help program (“Transform to Outperform”) and Alberta Path2Zero timing optionality; full deep‑dive below. (marketwatch.com)
2) Deep Dive: Dow Inc. (DOW)
2.1 What the business is today
- Segments: Packaging & Specialty Plastics (polyethylene and hydrocarbons), Industrial Intermediates & Infrastructure (polyurethanes/oxygenateds), Performance Materials & Coatings. Dow generated ~$43B sales in 2024 amid a downcycle; 2025 stayed soft. (investors.dow.com)
- Self‑help: In 2025 Dow cut its quarterly dividend from $0.70 to $0.35 to preserve flexibility and has continued cost actions. On January 29, 2026, management introduced “Transform to Outperform,” targeting ≥$2B near‑term operating EBITDA improvement and ~4,500 job reductions. (investors.dow.com)
- Network/footprint: Long‑run growth lever is Path2Zero in Alberta (net‑zero ethylene/PE complex). FID was 2023, but Dow delayed construction in April 2025 to align with weak markets and cut 2025 capex to ~$2.5B. (investors.dow.com)
- Liquidity and balance sheet: Net debt around ~$14.8B as of Mar 31, 2025 (Dow and TDCC basis); Q3‑25 cash was $4.6B. Dow also raised ~$2.4B in 2025 by selling 40% of “Diamond Infrastructure Solutions” to Macquarie, with an option for another ~$0.6B. Fitch downgraded to BBB in July 2025 on cycle weakness. (sec.gov)
- Latest prints: 3Q‑25 net sales $10.0B (−8% y/y) with sequential cash‑flow improvement; 4Q‑25 (reported Jan 29, 2026) came in better than feared per press coverage, alongside the $2B transformation plan. (investors.dow.com)
Why it screens as value now
- The stock trades near $27–$28 with an enterprise value around ~$33B, implying the market capitalizes trough‑cycle earnings with little credit for self‑help or mid‑cycle margins. (stockanalysis.com)
Market context that matters
- Global ethylene/PE remains oversupplied after a China‑led capacity wave; U.S. NGL feedstocks are cost‑advantaged but export policies add volatility (ethane export curbs vs. forecasts for rising exports). We underwrite a slow improvement from trough through 2027. (chemistryworld.com)
3) Ground‑up valuation: FCFF DCF + comparables
We build a conservative five‑year FCFF model, then triangulate with mid‑cycle EV/EBITDA.
Key anchors and cross‑references
- Revenue base: ~$40–41B in 2025 implied by press; 2024 actual $43.0B. We start 2026 at ~$41B (low single‑digit rebound). (investors.dow.com)
- Cost/efficiency: “Transform to Outperform” targets ≥$2B EBITDA uplift phased through 2026–2028; we include a portion of these savings in margin rebuild. (investing.com)
- Capex: 2025 cut to ~$2.5B due to Path2Zero delay; company had guided ~$3.0–3.2B for 2025 earlier. We assume $2.6–3.0B run‑rate 2026–2029, fading to $2.8B by 2030 as project phasing normalizes. (nasdaq.com)
- Shares and net debt: ~707–713M diluted average in 2025; net debt reference ~$14.8B (Mar 31, 2025). (investors.dow.com)
- Discount rate: risk‑free 10‑yr ≈4.25%; with beta ~1.2, ERP ~5.5–6%, cost of equity ≈11%. With BBB debt and tax shield, we use WACC 9.5% (bull 8.5%, bear 11%). (federalreserve.gov)
3.1 FCFF DCF (USD; 2026–2030 explicit)
Assumptions (our base case):
- Sales (2026→2030): $41.0B, $42.5B, $44.0B, $45.3B, $46.6B (≈2–3% CAGR).
- EBITDA margin rebuild: 11.0%, 12.5%, 13.5%, 14.5%, 15.0% as cycle heals and cost program accrues (still below 2021 peak). (investing.com)
- Depreciation: ~$3.0B/yr (rounded).
- Tax on EBIT: 23% effective.
- Capex: $2.6B (’26), $2.8B (’27), $3.0B (’28–’29), $2.8B (’30).
- Working capital: neutral over the cycle.
Implied FCFF (rounded):
- 2026: $1.56B
- 2027: $1.98B
- 2028: $2.26B
- 2029: $2.75B
- 2030: $3.27B
Discounting at 9.5% and using 1.5% terminal growth:
- PV(2026–2030 FCFF) ≈ $8.8B
- PV(Terminal) ≈ $26.4B
- Enterprise value ≈ $35.1B
- Less net debt ≈ $14.8B → Equity ≈ $20.3B
- Shares ≈ 711M → Intrinsic value ≈ $29/share (base). (sec.gov)
Sensitivity (per share, USD):
- Bull: WACC 8.5%, g 2.0%, a bit faster margin lift → ~$45.
- Bear: WACC 11.0%, g 0.5%, margins stall at low‑teens → ~$11–$18.
Why the range is reasonable: revenue/EBITDA paths reflect trough‑to‑mid‑cycle normalization and partial capture of the $2B EBITDA plan while recognizing global overcapacity/China self‑sufficiency headwinds. (chemistryworld.com)
3.2 Comparable checks
- Direct peers’ current EV/EBITDA prints are noisy at trough (e.g., WLK ≈10x TTM) but through‑cycle petrochemicals typically trade mid‑single‑digit to high‑single‑digit EV/EBITDA. We apply 5.5x–7.5x to a normalized Dow EBITDA of $5.0–$7.0B. Resulting EV range ≈ $27.5B–$52.5B → Equity ≈ $13B–$38B → ~$18–$53/share. A Barron’s analyst recently referenced a historical ~7x EBITDA yardstick for DOW as a cross‑check. (valueinvesting.io)
DCF–comps triangulation: fair value cluster ~$29 (base) with a wide cycle‑driven band of ~$18–$45.
4) Business roadmap and what could change the story
- Execute “Transform to Outperform”: deliver the staged EBITDA uplift (management framed ≥$2B) via model simplification, automation, and footprint actions. Proof points: quarterly run‑rate cost saves and margin progress in 2026–2027. (investing.com)
- Path2Zero timing: a restart of construction when markets justify it (company delayed in April 2025) could add $1B mid‑cycle EBITDA at full run rates later in the decade; project pacing will shape capex and free cash inflection. (investors.dow.com)
- Portfolio/infra monetization: the Macquarie partnership provided ~$2.4B cash with a path to ~$3B; more asset‑light moves could de‑risk capex. (investors.dow.com)
- Macro/fundamentals: watch ethane/PE spreads, export policy to China, and Europe rationalization; U.S. feedstock cost advantage remains, but trade policy can whipsaw margins. (tradingview.com)
What the market might be missing
- Trough optics vs. earnings power: 2025 losses and a dividend cut dominate headlines, but if EBITDA migrates back toward $5–7B mid‑cycle and the $2B program lands, equity math improves quickly even at conservative multiples. (marketwatch.com)
5) Risks and how they hit the model
- Prolonged price war/overcapacity: China’s self‑sufficiency and new global crackers keep margins low → our base margin glide would prove too optimistic. (chemistryworld.com)
- Policy/exports: U.S. ethane/PE export frictions to China could pressure utilization and spreads → lower EBITDA and slower DCF ramp. (We note conflicting projections; we model cautiously.) (tradingview.com)
- Project execution: Path2Zero delays or cost inflation would raise capex and defer cash returns; we phase modest spend post‑2026. (nasdaq.com)
- Credit/leverage: BBB rating and cycle leverage leave less room for error, though recent infra monetization helps. (ourmidland.com)
6) Investment view and price map
- Intrinsic value range (triangulated): ~$18–$45/share; base ~$29.
- At today’s ~$27–$28, DOW is near our base value with asymmetric upside if margins/EBITDA normalize and the $2B plan delivers. Accumulate on pullbacks into low‑$20s; trim above low‑$40s unless spreads and project execution clearly exceed plan.
- What would change our stance to negative: (i) failure to demonstrate tangible EBITDA uplift from “Transform to Outperform” by late‑2026, (ii) sustained EV/EBITDA < 5x mid‑cycle peers due to structurally lower profitability, (iii) capex creep without commensurate returns, (iv) export/policy regime that structurally impairs U.S. cracker economics. (investing.com)
7) Valuation “audit trail” — key sources
- Results and balance sheet (2024–2025): revenue, cash/debt, dividend reset, quarterly detail. (investors.dow.com)
- January 29, 2026 update: 4Q‑25 press coverage and “Transform to Outperform” ($2B EBITDA, ~4,500 jobs). (barrons.com)
- Path2Zero Alberta: FID and subsequent construction delay; capex pacing. (corporate.dow.com)
- Infrastructure partnership proceeds (Macquarie). (investors.dow.com)
- Credit and macro cycle checks (Fitch, ethane/exports, capacity backdrop). (ourmidland.com)
- Market data and EV snapshot (price, EV). (stockanalysis.com)
- Peer multiples/context. (valueinvesting.io)
8) Quick notes on how we modeled
- We used conservative revenue growth (≈2–3% CAGR) from a ~$40–41B trough base, below historical peaks, and a gradual margin rebuild below prior cycle highs. (investors.dow.com)
- The WACC of 9.5% reflects a 4.25% U.S. 10‑year plus equity and credit risk consistent with BBB cyclicals. (federalreserve.gov)
- Capex is aligned with the Path2Zero delay and public capex commentary; we hold working capital neutral over the full cycle. (nasdaq.com)
- Comparable EV/EBITDA checks are anchored to mid‑cycle ranges rather than trough TTM figures to avoid distortion. (valueinvesting.io)
Disclaimer: This independent analysis is for informational/educational purposes only and is not investment advice. All models are simplified, forward‑looking, and rely on public sources cited above; please do your own research and consider your objectives and risk tolerance.